Susumu Ishiguro1, Shuang Cai2,3, Deepthi Uppalapati1, Katie Turner1, Ti Zhang2, Wai Chee Forrest3, M Laird Forrest2,3, Masaaki Tamura4. 1. Department of Anatomy & Physiology, College of Veterinary Medicine, Kansas State University, 210 Coles Hall, Manhattan, Kansas, 66506, USA. 2. Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, Kansas, 66047, USA. 3. HylaPharm LLC, Lawrence, Kansas, 66047, USA. 4. Department of Anatomy & Physiology, College of Veterinary Medicine, Kansas State University, 210 Coles Hall, Manhattan, Kansas, 66506, USA. mtamura@vet.k-state.edu.
Abstract
PURPOSE: To determine aerosol administration capability and therapeutic efficacy of the new formulation of hyaluronan cisplatin conjugates, HylaPlat™ (HA-Pt), for lung cancer treatment. METHODS: In vitro formulation stability test, 2D and 3D spheroid cell culture and in vivo efficacy studies using mouse orthotopic allograft models were conducted. RESULTS: The HA-Pt effectively attenuated cell growth in 2D and 3D cultures with IC50 of 2.62 and 5.36 μM, respectively, which were comparable to those with unconjugated control cisplatin-dependent growth inhibition (IC50 1.64 and 4.63 μM, respectively). A single dose of either 7.5 or 15 mg/kg HA-Pt (cisplatin equivalent) by intratracheal aerosol spray 7 days after Lewis lung carcinoma (LLC) cell inoculation markedly inhibited growth of LLC allografts in mouse lungs and resulted in a 90 or 94% reduction of tumor nodule numbers, respectively, as compared to those from the PBS control. Cancer stem cells and cisplatin resistant cells marker, CD44 expression decreased in the tumor nodules of the HA-Pt but not in those of cisplatin treated groups. CONCLUSIONS: The current study suggests that an intratracheal aerosol administration of the HA-Pt nanoparticles offers an effective strategy for lung cancer treatment and this treatment may induce only limited cisplatin resistance.
PURPOSE: To determine aerosol administration capability and therapeutic efficacy of the new formulation of hyaluronan cisplatin conjugates, HylaPlat™ (HA-Pt), for lung cancer treatment. METHODS: In vitro formulation stability test, 2D and 3D spheroid cell culture and in vivo efficacy studies using mouse orthotopic allograft models were conducted. RESULTS: The HA-Pt effectively attenuated cell growth in 2D and 3D cultures with IC50 of 2.62 and 5.36 μM, respectively, which were comparable to those with unconjugated control cisplatin-dependent growth inhibition (IC50 1.64 and 4.63 μM, respectively). A single dose of either 7.5 or 15 mg/kg HA-Pt (cisplatin equivalent) by intratracheal aerosol spray 7 days after Lewis lung carcinoma (LLC) cell inoculation markedly inhibited growth of LLC allografts in mouse lungs and resulted in a 90 or 94% reduction of tumor nodule numbers, respectively, as compared to those from the PBS control. Cancer stem cells and cisplatin resistant cells marker, CD44 expression decreased in the tumor nodules of the HA-Pt but not in those of cisplatin treated groups. CONCLUSIONS: The current study suggests that an intratracheal aerosol administration of the HA-Pt nanoparticles offers an effective strategy for lung cancer treatment and this treatment may induce only limited cisplatin resistance.
Authors: Stephanie M Cohen; Ridhwi Mukerji; Shuang Cai; Ivan Damjanov; M Laird Forrest; Mark S Cohen Journal: Am J Surg Date: 2011-10-08 Impact factor: 2.565
Authors: Bart P H Wittgen; Peter W A Kunst; Kasper van der Born; Atie W van Wijk; Walter Perkins; Frank G Pilkiewicz; Roman Perez-Soler; Susan Nicholson; Godefridus J Peters; Pieter E Postmus Journal: Clin Cancer Res Date: 2007-04-15 Impact factor: 12.531
Authors: Elaine Lai-Han Leung; Ronald R Fiscus; James W Tung; Vicky Pui-Chi Tin; Lik Cheung Cheng; Alan Dart-Loon Sihoe; Louis M Fink; Yupo Ma; Maria Pik Wong Journal: PLoS One Date: 2010-11-19 Impact factor: 3.240
Authors: Shuang Cai; Ti Zhang; Chad Groer; Melanie Forrest; Daniel Aires; Vern Otte; Sally Barchman; Abby Faerber; Marcus Laird Forrest Journal: Case Rep Vet Med Date: 2018-10-08